Wall Street equity research analysts covering Outlook Therapeutics (OTLK) establish 12-month average price targets that reflect micro-cap biopharmaceutical valuations, hovering around $0.65 to $4.00 per share depending on the specific institutional consensus model. Analysts continuously adjust these targets based on commercial launch progress, revenue ramp-ups for its approved ophthalmic treatments, and future capital requirements.